Fuminori Sakurai

Dr. Fuminori Sakurai


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
FSFuminori Sakurai
Fuminori Sakurai
MTMasashi Tachibana
Masashi Tachibana
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi

4 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FSFuminori Sakurai
Fuminori Sakurai
SMSeiji Mitani
Seiji Mitani
TYTatsuro Yamamoto
Tatsuro Yamamoto
KTKazuo Takayama
Kazuo Takayama
MTMasashi Tachibana
Masashi Tachibana
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
In order to understand the life cycle of hepatitis B virus (HBV) and to develop efficient anti-HBV drugs, a usefulin vitrocell culture system which allows HBV infection and recapitulates virus-host interactions is essential; however, pre-existingin vitroHBV infection models are often problematic. Here, we examined the potential of human induced-pluripotent stem (iPS) cell-derived hepatocyte-like cells (iPS-HLCs) as anin vitroHBV infection model. Expression levels of several genes involved in HBV infection, including the sodium taurocholate cotransporting polypeptide (NTCP) gene, were gradually elevated as the differentiation status of human iPS cells proceeded to iPS-HLCs. The mRNA levels of these genes were comparable between primary human hepatocytes (PHHs) and iPS-HLCs. Following inoculation with HBV, we found significant production of HBV proteins and viral RNAs in iPS-HLCs. The three major forms of the HBV genome were detected in iPS-HLCs by Southern blotting analysis. Anti-HBV agents entecavir and Myrcludex-B, which are a nucleoside analogue reverse transcriptase inhibitor and a synthetic pre-S1 peptide, respectively, significantly inhibited HBV infection in iPS-HLCs. These data demonstrate that iPS-HLCs can be used as a promisingin vitroHBV infection model.

15 April 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
YKYuki Katayama
Yuki Katayama
MTMasashi Tachibana
Masashi Tachibana
NKNozomi Kurisu
Nozomi Kurisu
YOYukako Oya
Yukako Oya
YTYuichi Terasawa
Yuichi Terasawa
FSFuminori Sakurai
Fuminori Sakurai
Oncolytic reovirus, which possesses 10 segments of dsRNA genome, mediates antitumor effects via not only virus replication in a tumor cell–specific manner, but also activation of antitumor immunity; however, the mechanism(s) of reovirus-induced activation of antitumor immunity have not been fully elucidated. Recent studies have demonstrated that overcoming an immunosuppressive environment in tumor-bearing hosts is important to achieve efficient activation of antitumor immunity. Among the various types of cells involved in immunosuppression, it has been revealed that myeloid-derived suppressor cells (MDSCs) are significantly increased in tumor-bearing hosts and play crucial roles in the immunosuppression in tumor-bearing hosts. In this study, we examined whether reovirus inhibits the immunosuppressive activity of MDSCs, resulting in efficient activation of immune cells after in vivo administration. The results showed that splenic MDSCs recovered from PBS-treated tumor-bearing mice significantly suppressed the Ag-specific proliferation of CD8+ T cells. In contrast, the suppressive activity of MDSCs on T cell proliferation was significantly reduced after reovirus administration. Reovirus also inhibited the immunosuppressive activity of MDSCs in IFN-β promoter stimulator-1 knockout (KO) mice and in wild-type mice. In contrast, the immunosuppressive activity of MDSCs in TLR-3 KO mice was not significantly altered by reovirus treatment. The activation levels of CD4+ and CD8+ T cells were significantly lower in TLR3 KO mice than in wild-type mice after reovirus administration. These results indicate that reovirus inhibits the immunosuppressive activity of MDSCs in a TLR3, but not IFN-β promoter stimulator-1, signaling-dependent manner.

1 April 2018 in Biomaterials
Verified
Journal Article
Closed access
KTKazuo Takayama
Kazuo Takayama
YHYasuko Hagihara
Yasuko Hagihara
YTYukiko Toba
Yukiko Toba
KSKiyotoshi Sekiguchi
Kiyotoshi Sekiguchi
FSFuminori Sakurai
Fuminori Sakurai
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi

1 February 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TYTomoki Yamashita
Tomoki Yamashita
KTKazuo Takayama
Kazuo Takayama
FSFuminori Sakurai
Fuminori Sakurai
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi

1 January 2014 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
PDF file
KSKahori Shimizu
Kahori Shimizu
FSFuminori Sakurai
Fuminori Sakurai
KTKyoko Tomita
Kyoko Tomita
YNYasuhito Nagamoto
Yasuhito Nagamoto
SNShin-Ichiro Nakamura
Shin-Ichiro Nakamura
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
Leaky expression of adenovirus (Ad) genes occurs following transduction with a conventional replication-incompetent Ad vector, leading to an induction of cellular immunity against Ad proteins and Ad protein-induced toxicity, especially in the late phase following administration. To suppress the leaky expression of Ad genes, we developed novel Ad vectors by incorporating four tandem copies of sequences with perfect complementarity to miR-122a or miR-142-3p into the 3′-untranslated region (UTR) of the E2A, E4, or pIX gene, which were mainly expressed from the Ad vector genome after transduction. These Ad vectors easily grew to high titers comparable to those of a conventional Ad vector in conventional 293 cells. The leaky expression of these Ad genes in mouse organs was significantly suppressed by 2- to 100-fold, compared with a conventional Ad vector, by insertion of the miRNA-targeted sequences. Notably, the Ad vector carrying the miR-122a–targeted sequences into the 3′-UTR of the E4 gene expressed higher and longer-term transgene expression and more than 20-fold lower levels of all the Ad early and late genes examined in the liver than a conventional Ad vector. miR-122a–mediated suppression of the E4 gene expression in the liver significantly reduced the hepatotoxicity which an Ad vector causes via both adaptive and non-adaptive immune responses.